# A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

> **NCT06356571** · PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 64 (estimated)

## Conditions studied

- Plasma Cell Myeloma Refractory

## Interventions

- **DRUG:** Isatuximab SC-OBDS
- **DRUG:** Montelukast
- **DRUG:** Dexamethasone
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Methylprednisolone
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT06356571
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-17
- **Primary completion:** 2027-01-08
- **Final completion:** 2027-07-15
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356571, "A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06356571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*